Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


""Thailand's Low-Cost Generic Drugs Scheme A Boon For Poor (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Activists have praised Thailand for its recent decision to issue compulsory licenses for life-saving medications. These compulsory licenses temporarily remove patent protections on brand-name drugs. By doing so, Thailand will be able to import and produce less-expensive versions of these medications. Activists say Thailand is setting an example for developing nations who want to ensure quality healthcare for their citizens. Other countries, including Brazil, have already taken steps to institute similar programs. Major pharmaceutical companies have protested the Thai government's move arguing it is a violation of their intellectual property rights. However, experts say Thailand's actions are within the bounds of international law. So far, the country has issued compulsory licenses for the heart medication Plavix as well as AIDS treatments Kaletra and Efavirenz. Already generic versions of these drugs are flowing in from major Indian generics producers. In addition, the Thai government has announced it is also considering suspending patents for four cancer treatments. (Click here for more

You may also be interested in...

QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts